tiprankstipranks
Blueprint Medicines (BPMC)
NASDAQ:BPMC

Blueprint Medicines Stock Price & Analysis

454 Followers

BPMC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$43.46 - $117.86
Previous Close$65.57
Volume500.38K
Average Volume (3M)849.85K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$477.11M
Total Debt (Recent Filing)$82.73M
P/E Ratio-5.5
Beta0.69
Next EarningsOct 27, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-11.87
Shares Outstanding59,719,570
R-Squared0.07
Standard Deviation0.14
10 Day Avg. Volume596,177
30 Day Avg. Volume849,853
P/B Ratio5.24
P/S Ratio16.99
P/CF Ratio16.20
P/FCF Ratio-6.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside37.15% Upside
Rating ConsensusModerate Buy
Alpha0.00800
Number of Analyst Covering15


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

BPMC FAQ

What was Blueprint Medicines’s price range in the past 12 months?
Blueprint Medicines lowest stock price was $43.46 and its highest was $117.86 in the past 12 months.
    What is Blueprint Medicines’s market cap?
    Currently, no data Available
    When is Blueprint Medicines’s upcoming earnings report date?
    Blueprint Medicines’s upcoming earnings report date is Oct 27, 2022 which is in 31 days.
      How were Blueprint Medicines’s earnings last quarter?
      Blueprint Medicines released its earnings results on Aug 02, 2022. The company reported -$2.68 earnings per share for the quarter, missing the consensus estimate of -$2.239 by -$0.441.
        Is Blueprint Medicines overvalued?
        According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Blueprint Medicines pay dividends?
          Blueprint Medicines does not currently pay dividends.
          What is Blueprint Medicines’s EPS estimate?
          Blueprint Medicines’s EPS estimate is -$2.46.
            How many shares outstanding does Blueprint Medicines have?
            Blueprint Medicines has 59,719,570 shares outstanding.
              What happened to Blueprint Medicines’s price movement after its last earnings report?
              Blueprint Medicines reported an EPS of -$2.68 in its last earnings report, missing expectations of -$2.239. Following the earnings report the stock price went up 11.245%.
                Which hedge fund is a major shareholder of Blueprint Medicines?
                Among the largest hedge funds holding Blueprint Medicines’s share is Farallon Capital Management, L.L.C.. It holds Blueprint Medicines’s shares valued at 61M.

                  ---

                  Blueprint Medicines Stock Analysis

                  Smart ScoreNeutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  6
                  The Blueprint Medicines stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Blueprint Medicines

                  Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis